Brazil's health regulators have approved Telix Pharmaceuticals' nuclear imaging agent for prostate cancer, Illucix. ... Read ...

In a report released today, Shane Storey from Wilsons maintained a Buy rating on Telix Pharmaceuticals Ltd. (TLPPF – Research Report), with a ...

Lead-212 is a promising radioactive isotope for use in targeted alpha therapy, an alternative modality to beta-particle-based ...

Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that it has developed and validated ...

Melbourne-based biotech Telix Pharmaceuticals has announced that its prostate cancer diagnostic agent Illuccix has been ...

MELBOURNE, Australia and PORTO ALEGRE, Brazil, March 18, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, ...

William Blair restated their outperform rating on shares of Telix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX – Free Report) in a research note released on Wednesday ...

TLX opened at $17.30 on Friday. The firm’s fifty day simple moving average is $17.47. Telix Pharmaceuticals Limited American Depositary Shares has a 52-week low of $14.01 and a 52-week high of $30.36.

The high-flying S&P/ASX 200 Index (ASX: XJO) share made a major acquisition announcement. Here’s what you need to know.

MELBOURNE, Australia and INDIANAPOLIS, March 13, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that it has developed and validated ...